DMRADamora Therapeutics, Inc.Healthcare · Biotechnologyas of 2026-09-16
Horizon

Issued 2026-09-16 at $24.53 · now $24.53 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, DMRA has typically landed between $16.30 and $36.82 — a range of −33.6% to +50.1% from the issuance price $24.53.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

1,451 overlapping 1 month windows · 2020-10-292026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.756.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($24.53) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where DMRA has typically landed a month from the 2026-09-16 close of $24.53 — the range is history, not a prediction.

$16.3worst · -33.6%$36.82best · +50.1%
  • now $24.53 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $24.11 (-1.7%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $20.73$27.48
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $16.3$36.82
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 1,451 windows spanning 2020-10-29 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2023-07-27−81.6%−81.6%+1.3%
2023-07-26−81.5%−81.5%+0.0%
2023-07-31−81.1%−81.8%+0.0%
3 best
2025-11-07+494.9%+0.0%+494.9%
2025-09-09+471.7%+0.0%+471.7%
2025-11-06+377.5%−14.9%+378.4%

1,451 overlapping windows · 2020-10-292026-09-16 · not cherry-picked

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~6 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
50%
+14.0%
n=6
Feb
33%
−4.2%
n=6
Mar
33%
−10.8%
n=6
Apr
0%
−10.8%
n=6
May
33%
−1.5%
n=6
Jun
67%
+6.1%
n=6
Jul
50%
+4.5%
n=6
Aug
33%
−10.7%
n=6
Sep
50%
−1.1%
n=6
Oct
40%
+5.0%
n=5
Nov
50%
+17.5%
n=6
Dec
50%
−1.0%
n=6

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$34$32026-07-06: 1 insider sale, $7K — Winslow Garrett2026-07: 1 open-market sale, $7K↑ buys↓ salesofficer Winslow Garrett — Sale on 2026-07-06, filed 1 day after the trade
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling
2026-07-06Winslow GarrettofficerSale245 @ $29.98$7K−9.7% of holding−1.9%not yet — horizon still open2,289Form 4 · filed 1 day after the trade

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

12 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-08-12Cheng AndrewdirectorAward / grant30,35030,350Form 4
2026-07-03Winslow GarrettofficerOption exercise680640Form 4
2026-07-03Winslow GarrettofficerOption exercise6802,534Form 4
2026-07-03Winslow GarrettofficerOption exercise6802,534Form 4
2026-03-30Jarrett JenniferdirectorAward / grant500,000500,000Form 4
2026-03-30Jarrett JenniferdirectorAward / grant1,500,0001,500,000Form 4
2026-03-23Winslow GarrettofficerAward / grant250,000250,000Form 4
2026-03-23Fairmount Funds Management LLCdirectorAward / grant37,31337,313Form 4
2026-03-23Landsittel MichaeldirectorAward / grant37,31337,313Form 4
2026-03-23Bruno JuliannedirectorAward / grant37,31337,313Form 4
2026-03-23CAIN CHRISTOPHER W.directorAward / grant37,31337,313Form 4
2026-03-23Turtle CamerondirectorAward / grant37,31337,313Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.